直接口服抗凝药对接受腔内射频和激光消融的患者可能是安全的
该回顾性研究纳入2018至2020年因症状性大/小隐静脉反流接受射频或1470nm激光消融的301例患者(382次手术),比较围术期治疗剂量直接口服抗凝药(DOAC)组与对照组的疗效与安全性。结果显示DOAC组无出血、深静脉血栓(DVT)及热诱导血栓(EHIT),9个月闭合率与对照组无显著差异,多变量分析DOAC使用未增加再通风险(HR 5.76,95%CI 0.57-58.64,P=0.139)。
要点
- DOAC组围术期无出血、DVT及EHIT事件,对照组DVT发生率为0.7%。
- 9个月闭合率DOAC组94.4% vs 对照组98.4%(P=0.163),无显著差异。
- 多变量分析DOAC使用与再通风险无显著关联(HR 5.76,95%CI 0.57-58.64)。
核心结论
- 围术期使用DOAC未对腔内消融至9个月以上的疗效产生不良影响。
- DOAC使用未增加围术期出血、DVT或EHIT的额外风险。
- DOACs可能可以安全持续使用而不影响腔内热消融的疗效和持久性。
研究设计与样本
- 回顾性研究,纳入2018至2020年因症状性大或小隐静脉反流接受射频消融或1470nm二极管激光腔内激光消融的患者。
- 共301例患者(382次手术),分为围术期接受治疗剂量DOAC组69例(87次手术)和未接受DOAC的对照组232例(295次手术)。
主要发现
- DOAC组患者较对照组年龄更大(平均65岁 vs 55岁;P<.001)、男性比例更高(70% vs 37%;P<.001)。
- DOAC组静脉血栓栓塞症病史比例更高(44% vs 6%;P<.001),肺栓塞病史比例更高(13% vs 0%;P<.001),静脉炎病史比例更高(32% vs 15%;P<.001)。
- 对照组射频消融使用比例更高(92% vs 84%;P=.029),治疗静脉段更长(平均38 mm vs 35 mm;P=.028)。
- 两组均无大或小出血事件,也无EHIT发生;对照组2例(0.7%)发生DVT,DOAC组无DVT(P=.441)。
- 9个月时DOAC组94.4%的手术维持消融,对照组98.4%(P=.163);多变量分析DOAC使用与再通风险无显著关联(HR 5.76;95%CI 0.57-58.64;P=.139),术前静脉直径增大和使用腔内激光消融与再通风险增加相关。
临床怎么用
- 作者认为DOACs可能可以安全持续使用而不影响腔内热消融的疗效和持久性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Studies assessing the effect of the use of anticoagulant agents on endovenous thermal ablation (ETA) have been limited to patients taking warfarin. Thus, the aim of the present study was to assess the efficacy and safety of ETA for patients taking direct oral anticoagulants (DOACs). We hypothesized that the outcome of ETA for patients taking DOACs would not be superior to the outcomes for patients taking DOACs. METHODS: We performed a retrospective review to identify patients who had undergone radiofrequency ablation or endovenous laser ablation with 1470-nm diode laser fibers for symptomatic great or small saphenous venous reflux from 2018 to 2020. The patients were dichotomized into those who had received a therapeutic dose of DOACs periprocedurally and those who had not (control group). The outcomes of interest included the rates of treated vein closure at 7 days and 9 months and the incidence of deep vein thrombosis (DVT), endothermal heat-induced thrombosis (EHIT), and bleeding periprocedurally. RESULTS: Of the 301 patients (382 procedures), 69 patients (87 procedures) had received DOACs and 232 control patients (295 procedures) had not received DOACs. The patients receiving DOACs were more often older (mean age, 65 years vs 55 years; P < .001) and male (70% vs 37%; P < .001), with a higher prevalence of venous thromboembolism and more severe CEAP (clinical, etiologic, anatomic, pathophysiologic) classification (5 or 6), than were the control patients. Those receiving DOACs were more likely to have had a history of DVT (44% vs 6%; P < .001), pulmonary embolism (13% vs 0%; P < .001), and phlebitis (32% vs 15%; P < .001). Procedurally, radiofrequency ablation had been used more frequently in the control group (92% vs 84%; P = .029), with longer segments of treated veins (mean, 38 mm vs 35 mm, respectively; P = .028). No major or minor bleeding events nor any EHIT had occurred in either group. Two patients in the control group (0.7%) developed DVT; however, no DVT was observed in those in the DOAC group (P = .441). At 9 months, the treated vein had remained ablated after 94.4% of procedures for patients receiving DOACs and 98.4% of the control group (P = .163). On multivariable analysis, DOAC usage was not associated with an increased risk of vein recanalization (hazard ratio, 5.76; 95% confidence interval, 0.57-58.64; P = .139). An increased preprocedural vein diameter and the use of endovenous laser ablation were associated with an increased risk of recanalization. CONCLUSIONS: In our study of patients who had undergone ETA for symptomatic saphenous venous reflux, the periprocedural use of DOACs did not adversely affect the efficacy of endovenous ablation to ≥9 months. Furthermore, DOAC use did not confer an additional risk of bleeding, DVT, or EHIT periprocedurally. DOACs may be safely continued without affecting the efficacy and durability of ETA.
引用
- Chang H, Sadek M, Barfield ME, et al. Direct oral anticoagulant agents might be safe for patients undergoing endovenous radiofrequency and laser ablation. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35872143. doi:10.1016/j.jvsv.2022.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。